US stock · Healthcare sector · Diagnostics & Research
Company Logo

Charles River Laboratories International, Inc.

CRLNYSE

246.91

USD
-3.44
(-1.37%)
After Hours Market
28.88P/E
22Forward P/E
1.31P/E to S&P500
12.562BMarket CAP
- -Div Yield
Upcoming Earnings
14 Feb-20 Feb
Shares Short
1/13/23
1.02M
Short % of Float
2.60%
Short % of Shares Outs.
2.01%
% Held by Insiders
1.04%
% Held by Institutions
101.56%
Beta
1.32
PEG Ratio
2.27
52w. high/low
349.84/181.36
Avg. Daily Volume
0.59M
Return %
Stock
S&P 500
1 year
(25.11)
(7.99)
3 years
57.77
23.80
5 years
150.95
56.27
Scale: |
High
Low
69.19
19.92
40.14
23.03
41.65
26.82
42.84
25.52
41.64
27.02
53.81
37.38
66.11
49.60
84.69
59.99
89.18
65.70
119.05
75.25
139.72
96.70
153.39
103.00
257.88
95.58
460.21
243.37
376.80
181.43
260.52
215.11
Currency: USD
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
15.37
18.41
19.97
18.40
18.12
22.48
23.58
24.41
27.83
29.32
35.76
39.12
47.26
53.79
59.01
70.39
74.58
Earnings per share
(0.81)
2.31
(7.76)
1.75
(5.38)
2.16
2.03
2.15
2.72
3.21
3.29
2.60
4.72
5.17
7.35
7.77
8.62
FCF per share
(0.25)
0.86
1.23
2.22
2.02
3.07
3.35
3.52
4.16
4.80
5.17
4.92
6.28
6.99
7.67
10.58
5.52
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
2.64
3.40
2.93
1.22
0.69
0.97
0.99
0.82
1.22
1.36
1.18
1.74
2.92
2.88
3.36
4.55
6.60
Book Value per sh.
23.16
27.83
17.82
21.04
10.99
10.34
12.54
13.43
14.42
15.77
17.80
22.01
27.47
33.54
42.68
50.40
51.38
Comm.Shares outs.
69
67
67
65
63
51
48
48
47
46
47
47
48
49
50
50
51
Avg. annual P/E ratio
- -
22.6
(7.0)
17.7
(6.3)
16.4
17.6
20.9
21.3
22.4
23.8
37.4
24.6
26.0
25.6
45.6
28.9
P/E to S&P500
- -
1.3
(0.3)
0.2
(0.3)
1.0
1.2
1.2
1.2
1.1
1.1
1.6
1.0
1.1
0.7
1.5
1.3
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
1,058
1,231
1,343
1,203
1,133
1,143
1,130
1,166
1,298
1,363
1,681
1,858
2,266
2,621
2,924
3,540
3,781
Operating margin
17.8%
18.5%
(33.5)%
13.9%
(26.3)%
15.3%
14.7%
13.0%
13.7%
15.1%
14.1%
15.5%
14.6%
13.4%
14.8%
16.7%
17.5%
Depreciation (m)
85
89
91
94
94
85
81
97
96
95
127
131
162
198
235
266
294
Net profit (m)
(56)
154
(522)
114
(337)
110
97
103
127
149
155
123
226
252
364
391
436
Income tax rate
28.2%
27.3%
(13.4)%
26.6%
(0.0)%
12.9%
21.3%
23.8%
26.8%
22.2%
30.0%
57.7%
19.3%
16.5%
18.3%
17.0%
18.1%
Net profit margin
(5.3)%
12.5%
(38.8)%
9.5%
(29.7)%
9.6%
8.6%
8.8%
9.8%
11.0%
9.2%
6.6%
10.0%
9.6%
12.5%
11.0%
11.6%
Working capital (m)
242
305
317
346
293
209
143
306
311
247
227
363
340
311
361
241
401
Long-term debt (m)
547
485
541
457
670
703
527
642
746
846
1,208
1,114
1,637
1,966
2,085
2,917
3,306
Equity (m)
1,595
1,860
1,199
1,375
687
526
601
641
672
733
837
1,045
1,317
1,635
2,115
2,535
2,627
ROIC
(0.2)%
6.2%
(27.2)%
6.6%
(20.5)%
11.0%
10.0%
8.7%
8.8%
9.4%
7.7%
5.6%
8.5%
7.7%
9.4%
7.6%
7.4%
Return on capital
(0.2)%
7.6%
(20.6)%
8.0%
(17.4)%
10.9%
10.0%
9.7%
10.1%
10.2%
9.3%
11.1%
9.0%
7.8%
9.8%
7.8%
7.8%
Return on equity
(3.5)%
8.3%
(43.5)%
8.3%
(49.0)%
20.8%
16.2%
16.0%
18.8%
20.4%
18.5%
11.8%
17.2%
15.4%
17.2%
15.4%
16.6%
Plowback ratio
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
(21.6)%
- -
31.6%
- -
181.8%
40.0%
98.8%
62.9%
52.7%
5.0%
45.7%
4.6%
5.3%
6.3%
7.7%
13.9%
Capital Structure
2 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 4,711
Total assets
$ 7,383
Long-term debt
$ 3,306
Cash and equiv.
$ 194
Goodwill
$ 2,776
Retained earnings
$ 1,280
Common stock
51
Enterprise Value
$ 15,675
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
239
229
242
Receivables
514
618
650
Inventory
161
186
199
Other
108
159
185
Current assets
1,021
1,201
1,274
Acc. Payable
111
122
198
Debt due
59
75
36
Other
540
642
799
Current liabilities
710
840
1,033
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
21.08%
17.57%
13.74%
Cash flow
40.00%
23.36%
14.87%
Earnings
7.32%
36.68%
19.65%
Dividends
- -
- -
- -
Book value
19.87%
24.84%
17.67%
Insider Trading
Type
Shares
Date
Creamer Victoria L
InKind
2,692
01/31/23
Foster James C
InKind
21,453
01/27/23
Foster James C
Award
49,725
01/27/23
Parisotto Shannon M
InKind
1,309
01/27/23
Parisotto Shannon M
Award
4,820
01/27/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
707
683
743
791
2,924
2021
825
915
896
905
3,540
2022
914
973
989
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.02
1.36
2.08
2.89
7.35
2021
1.22
1.76
2.06
2.74
7.77
2022
1.84
2.15
1.90
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Mr. James Foster
Full-time employees:
18,600
City:
Wilmington
Address:
251 Ballardvale St
IPO:
Jun 23, 2000
Website:
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.